期刊
AAPS JOURNAL
卷 16, 期 6, 页码 1204-1213出版社
SPRINGER
DOI: 10.1208/s12248-014-9671-y
关键词
antigen-specific immunotherapy; B7/CD28:CTLA-4 co-stimulatory pathway; experimental autoimmune encephalomyelitis (EAE); proteolipid peptide; soluble antigen array
资金
- NIH [1R56AI091996-01A1]
- KINBRE [P20 RR016475/P20 GM103418]
- American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship in Clinical Pharmaceutical Science
- Takeru Higuchi Graduate Fellowship (University of Kansas)
Autoimmune diseases such as multiple sclerosis (MS) are characterized by the breakdown of immune tolerance to autoantigens. Targeting surface receptors on immune cells offers a unique strategy for reprogramming immune responses in autoimmune diseases. The B7 signaling pathway was targeted using adaptations of soluble antigen array (SAgA) technology achieved by covalently linking B7-binding peptides and disease causing autoantigen (proteolipid peptide (PLP)) to hyaluronic acid (HA). We hypothesized that co-delivery of a B7-binding peptide and autoantigen would suppress experimental autoimmune encephalomyelitis (EAE), a murine model of MS. Three independent B7-targeted SAgAs were created containing peptides to either inhibit or potentially stimulate the B7 signaling pathway. Surprisingly, all SAgAs were found to suppress EAE disease symptoms. Altered cytokine expression was observed in primary splenocytes isolated from SAgA-treated mice, indicating that SAgAs with different B7-binding peptides may suppress EAE through different immunological mechanisms. This antigen-specific immunotherapy using SAgAs can successfully suppress EAE through co-delivery of autoantigen and peptides targeting with the B7 signaling pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据